Table 4.
Demographic and clinical characteristics of patients with low and high uFABP3/uCr.
| Low uFABP3/uCr | High uFABP3/uCr | P | |
|---|---|---|---|
| (n = 79) | (n = 135) | ||
| Mean (SD) ‡ | |||
| Age, years | 65 (12) | 70 (9) | 0.003 |
| Ankle brachial index | 0.84 (0.26) | 0.73 (0.24) | 0.006 |
| Demographics/comorbidities: N (%) ¶ | |||
| Peripheral artery disease | 35 (38) | 112 (83) | 0.001 |
| Sex, male | 58 (73) | 86 (64) | 0.18 |
| Hypertension | 46 (59) | 97 (72) | 0.06 |
| Dyslipidemia | 53 (68) | 109 (81) | 0.035 |
| Diabetes | 17 (22) | 45 (33) | 0.07 |
| Smoking (current and past) | 66 (84) | 112 (83) | 0.91 |
| Coronary artery disease | 22 (28) | 41 (31) | 0.67 |
| Medications: N (%) ¶ | |||
| Statins | 56 (74) | 108 (81) | 0.20 |
| ACE-I/ARB | 34 (45) | 75 (57) | 0.09 |
| Beta blockers | 21 (28) | 40 (30) | 0.68 |
| Diuretics | 5 (7) | 11 (8) | 0.64 |
| ASA | 44 (56) | 79 (59) | 0.69 |
| Antiplatelets (Other than ASA) | 17 (22) | 24 (18) | 0.50 |
| Rivaroxaban (low dose 2.5 mg oral twice daily) | 1 (1) | 3 (2) | 0.62 |
| Events: N (%) ¶ | |||
| MALE | 3 (4) | 19 (14) | 0.034 |
| Vascular intervention | 3 (4) | 16 (12) | 0.046 |
| Major amputation | 0 (0) | 3 (2) | 0.18 |
| Worsening PAD (drop in ABI ≥ 0.15) | 1 (1) | 27 (22) | 0.001 |
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; MALE, major adverse limb event: composite of vascular intervention and major amputation; PAD, peripheral artery disease; ABI, ankle brachial index.; uFABP3/uCr [urinary fatty acid binding protein 3 (uFABP3) normalized to urinary creatinine (uCr)]; Low uFABP3/uCr defined as ≤ 2.70 μg/g; High uFABP3/uCr defined as >2.70 μg/g;
‡
Compared using independent t-test;
¶
Compared using chi-square test. Bold values represent statistically significant values (p < 0.05).